Bone Therapeutics completes recruitment for spinal fusion study: 4 things to know

Megan Wood -   Print  |

Bone Therapeutics finished patient recruitment for its Phase IIA lumbar spinal fusion study.

Here are four things to know:


1. The study will test the ALLOB, the company's allogeneic bone-cell therapy product.


2. Bone Therapeutics anticipates having efficacy and safety data for the 32 patients by mid-2019.


3. The study will follow the patients for 12 months.


4. The interim results of the study revealed bone formation and pain improvement in patients with ALLOB.


More articles on biologics:
Positive clinical trial results for human dermal fibroblast injection CybroCell: 7 key insights
Stempeutics Research inks deal with Alkem Laboratories for osteoarthritis drug: 3 insights
Bioventus to be sole US distributor of Supartz Fx through May 2028 — 3 things to know


© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers